VJHemOnc is committed to improving our service to you

ASH 2019 | MRD-based response-adapted consolidation in NDMM post-transplant

VJHemOnc is committed to improving our service to you

Luciano Costa

Luciano Costa, MD, PhD, University of Alabama at Birmingham, Birmingham, AL, explains the first report of a monoclonal antibody-based quadruplet regimen with MRD-based response-adapted therapy in newly diagnosed multiple myeloma. Daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) indcution, followed by autologous transplant and MRD-guided Dara-KRd consolidation was given with promising results. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter